236 related articles for article (PubMed ID: 26280679)
1. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.
Sanford RA; Song J; Gutierrez-Barrera AM; Profato J; Woodson A; Litton JK; Bedrosian I; Albarracin CT; Valero V; Arun B
Cancer; 2015 Oct; 121(19):3422-7. PubMed ID: 26280679
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications for BRCA gene mutation in breast cancer.
Xu J; Wang B; Zhang Y; Li R; Wang Y; Zhang S
Mol Biol Rep; 2012 Mar; 39(3):3097-102. PubMed ID: 21691706
[TBL] [Abstract][Full Text] [Related]
3. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
4. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
[TBL] [Abstract][Full Text] [Related]
5. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Atchley DP; Albarracin CT; Lopez A; Valero V; Amos CI; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
J Clin Oncol; 2008 Sep; 26(26):4282-8. PubMed ID: 18779615
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
Guzmán-Arocho YD; Rosenberg SM; Garber JE; Vardeh H; Poorvu PD; Ruddy KJ; Kirkner G; Snow C; Tamimi RM; Peppercorn J; Schapira L; Borges VF; Come SE; Brachtel EF; Marotti JD; Warner E; Partridge AH; Collins LC
Br J Cancer; 2022 Feb; 126(2):302-309. PubMed ID: 34703009
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.
Yip CH; Taib NA; Choo WY; Rampal S; Thong MK; Teo SH
World J Surg; 2009 Oct; 33(10):2077-81. PubMed ID: 19649760
[TBL] [Abstract][Full Text] [Related]
9. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast Cancer.
Bukamal Z; AlRayes A
Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
[TBL] [Abstract][Full Text] [Related]
11. Pathological characteristics of BRCA-associated breast cancers in Hispanics.
Lagos-Jaramillo VI; Press MF; Ricker CN; Dubeau L; Mai PL; Weitzel JN
Breast Cancer Res Treat; 2011 Nov; 130(1):281-9. PubMed ID: 21604016
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
13. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
Akkoc Mustafayev FN; Shukla MA; Lanier A; Milton DR; Gutierrez AM; Gruschkus SK; Lewis JE; Murthy RK; Arun BK
Cancer; 2024 May; 130(9):1600-1608. PubMed ID: 38100492
[TBL] [Abstract][Full Text] [Related]
15. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
16. BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer.
Kim S; Rimm D; Carter D; Khan A; Parisot N; Franco MA; Bale A; Haffty BG
Breast J; 2003; 9(3):167-74. PubMed ID: 12752624
[TBL] [Abstract][Full Text] [Related]
17. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
18. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
[TBL] [Abstract][Full Text] [Related]
20. What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?
Forester E; Belsare A; Kim DW; Whitaker K; Obeid E; Goldstein LJ; Bleicher RJ; Daly MB; Williams AD
J Surg Res; 2024 Jul; 299():217-223. PubMed ID: 38776577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]